SGLT2 inhibitors improve cardiovascular outcomes across groupsJanuary 7, 2022DiabetesHeart FailurePreventive CareStrokeAcute Coronary Syndromes
Cardiac device interrogation after death ‘richly informative’January 3, 2022Arrhythmias & EPHeart FailureAcute Coronary Syndromes
Small myocarditis risk now seen for adenovirus-based COVID-19 vaccineDecember 20, 2021Heart FailureCOVID-19 Updates
New data on rare myocarditis after COVID-19 vaccinationDecember 8, 2021COVID-19 UpdatesAcute Coronary SyndromesHeart Failure
AHA challenges diet doctor’s study alleging COVID vax risksDecember 8, 2021Heart FailureCOVID-19 Updates
SGLT2 inhibitor use tied to fewer atrial arrhythmiasDecember 2, 2021Arrhythmias & EPHeart FailureDiabetes
Could an oral PCSK9 inhibitor be on the horizon?November 30, 2021Heart FailureDiabetesLipid Disorders
Empagliflozin a winner in challenging arena of stabilized acute HFNovember 19, 2021Heart FailureCAD & AtherosclerosisDiabetes
DREAM-HF: Negative stem cell trial in heart failure may still offer promiseNovember 16, 2021Heart Failure
EHRs have no impact on inpatient heart failure clinical choices or outcomesNovember 15, 2021Heart FailureBusiness of Medicine
Finerenone, sotagliflozin exert heart failure benefits despite renal dysfunctionNovember 14, 2021Heart FailureDiabetes
BP Track: Blood pressure control rates dropped during pandemicNovember 14, 2021HypertensionHeart Failure
